Cancer genomics identifies disrupted epigenetic genes

[1]  Amit Verma,et al.  Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer , 2013, Nucleic acids research.

[2]  M. Esteller,et al.  Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis , 2013, Oncogene.

[3]  R. Gilbert,et al.  Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. , 2013, Carcinogenesis.

[4]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[5]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[6]  S. Ishikawa,et al.  Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features , 2013, Cancer science.

[7]  Limin Liu,et al.  Insertion/Deletion Polymorphisms in the Promoter Region of BRM Contribute to Risk of Hepatocellular Carcinoma in Chinese Populations , 2013, PloS one.

[8]  M. Shan,et al.  Promoter Hypermethylation of ARID1A Gene Is Responsible for Its Low mRNA Expression in Many Invasive Breast Cancers , 2013, PloS one.

[9]  G. Mills,et al.  Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.

[10]  F. Bertucci,et al.  Mutations and deletions of ARID1A in breast tumors , 2012, Oncogene.

[11]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[12]  S. Armstrong,et al.  Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia , 2012, Leukemia.

[13]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[14]  Alfonso Valencia,et al.  Distinct DNA methylomes of newborns and centenarians , 2012, Proceedings of the National Academy of Sciences.

[15]  M. Esteller,et al.  Intronic RNAs mediate EZH2 regulation of epigenetic targets , 2012, Nature Structural &Molecular Biology.

[16]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[17]  M. Weller,et al.  Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma , 2012, PloS one.

[18]  M. Zhou,et al.  The von Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C , 2012, Oncogene.

[19]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[20]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[21]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[22]  K. Schulten,et al.  Recognition of methylated DNA through methyl-CpG binding domain proteins , 2011, Nucleic acids research.

[23]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[24]  M. Esteller,et al.  Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer , 2011, Oncogene.

[25]  H. Stunnenberg,et al.  Towards cracking the epigenetic code using a combination of high‐throughput epigenomics and quantitative mass spectrometry‐based proteomics , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[26]  M. Esteller,et al.  DNMT3B gene amplification predicts resistance to DNA demethylating drugs , 2011, Genes, chromosomes & cancer.

[27]  R. Schneider,et al.  Histone modifiers in cancer: friends or foes? , 2011, Genes & cancer.

[28]  David A. Orlando,et al.  The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset , 2011, Nature.

[29]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[30]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[31]  D. Pisano,et al.  Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors , 2011, Human mutation.

[32]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[33]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[34]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[35]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[36]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[37]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[38]  S. Robson,et al.  Nucleosome-Interacting Proteins Regulated by DNA and Histone Methylation , 2010, Cell.

[39]  Hiroyuki Yamamoto,et al.  A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. , 2010, Cancer cell.

[40]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[41]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[42]  Edwin Smith,et al.  The Language of Histone Crosstalk , 2010, Cell.

[43]  Jacqueline S. Garcia,et al.  Oncotargets and Therapy Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress an Update on the Safety and Efficacy of Decitabine in the Treatment of Myelodysplastic Syndromes , 2022 .

[44]  Yang Shi,et al.  Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. , 2010, Annual review of biochemistry.

[45]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[46]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[47]  Miguel Alaminos,et al.  Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma , 2009, Proceedings of the National Academy of Sciences.

[48]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[49]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Martinka,et al.  Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma , 2009, Clinical Cancer Research.

[51]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[52]  P. Farnham.  Insights from genomic profiling of transcription factors , 2009, Nature Reviews Genetics.

[53]  Gretchen M. Williams,et al.  DICER1 Mutations in Familial Pleuropulmonary Blastoma , 2009, Science.

[54]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[55]  D. Spector,et al.  Long noncoding RNAs: functional surprises from the RNA world. , 2009, Genes & development.

[56]  Eran Segal,et al.  From DNA sequence to transcriptional behaviour: a quantitative approach , 2009, Nature Reviews Genetics.

[57]  B. Cairns,et al.  The biology of chromatin remodeling complexes. , 2009, Annual review of biochemistry.

[58]  Howard Y. Chang,et al.  Genome-wide views of chromatin structure. , 2009, Annual review of biochemistry.

[59]  A. Shilatifard,et al.  An operational definition of epigenetics. , 2009, Genes & development.

[60]  T. Shaikh,et al.  Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors , 2009, Clinical Cancer Research.

[61]  Carla Oliveira,et al.  A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function , 2009, Nature Genetics.

[62]  Andrew H Coles,et al.  The ING gene family in the regulation of cell growth and tumorigenesis , 2009, Journal of cellular physiology.

[63]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[64]  Michael Q. Zhang,et al.  Combinatorial patterns of histone acetylations and methylations in the human genome , 2008, Nature Genetics.

[65]  M. Toyota,et al.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. , 2008, Cancer research.

[66]  H. Hibshoosh,et al.  BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. , 2008, Cancer research.

[67]  U. Lehmann,et al.  Epigenetic inactivation of microRNA gene hsa‐mir‐9‐1 in human breast cancer , 2008, The Journal of pathology.

[68]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[69]  S. Dhanasekaran,et al.  Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. , 2007, Cancer cell.

[70]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[71]  John Lough,et al.  Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response , 2007, Nature.

[72]  E. Verdin,et al.  Sirtuins: critical regulators at the crossroads between cancer and aging , 2007, Oncogene.

[73]  G. Wang,et al.  NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis , 2007, Nature Cell Biology.

[74]  A. Mortazavi,et al.  Genome-Wide Mapping of in Vivo Protein-DNA Interactions , 2007, Science.

[75]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[76]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[77]  Nathaniel D. Heintzman,et al.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome , 2007, Nature Genetics.

[78]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[79]  Bing Li,et al.  The Role of Chromatin during Transcription , 2007, Cell.

[80]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[81]  Peter A. Jones,et al.  Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. , 2006, Cancer cell.

[82]  Q. Wei,et al.  DNMT3b Polymorphism and Hereditary Nonpolyposis Colorectal Cancer Age of Onset , 2006, Cancer Epidemiology Biomarkers & Prevention.

[83]  L. Aaltonen,et al.  A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition , 2006, Nature Genetics.

[84]  A. Bird,et al.  Genomic DNA methylation: the mark and its mediators. , 2006, Trends in biochemical sciences.

[85]  A. Feinberg,et al.  Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. , 2005, Cancer research.

[86]  W. Lam,et al.  Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells , 2005, Nature Genetics.

[87]  Manel Esteller,et al.  How epigenetics integrates nuclear functions , 2005 .

[88]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[89]  Wolf Reik,et al.  Co-evolution of X-chromosome inactivation and imprinting in mammals , 2005, Nature Reviews Genetics.

[90]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[91]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[92]  Eric S. Lander,et al.  Genomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse , 2005, Cell.

[93]  T. Golub,et al.  Conditional MLL‐CBP targets GMP and models therapy‐related myeloproliferative disease , 2005, The EMBO journal.

[94]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[95]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[96]  Yusuke Nakamura,et al.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells , 2004, Nature Cell Biology.

[97]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[98]  B. Turner,et al.  Immunoprecipitation of native chromatin: NChIP. , 2003, Methods.

[99]  S. Mathew,et al.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.

[100]  Peter Nürnberg,et al.  Evaluation of a potential epigenetic biomarker by quantitative methyl‐single nucleotide polymorphism analysis , 2002, Electrophoresis.

[101]  Hongbing Shen,et al.  A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. , 2002, Cancer research.

[102]  Manel Esteller,et al.  DNA methylation: a profile of methods and applications. , 2002, BioTechniques.

[103]  M. Peinado,et al.  Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). , 2002, Nucleic acids research.

[104]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[105]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[106]  D. Teng,et al.  BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. , 2000, Cancer research.

[107]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[108]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[109]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[110]  T. Huang,et al.  Methylation profiling of CpG islands in human breast cancer cells. , 1999, Human molecular genetics.

[111]  C. Walsh,et al.  Transcription of IAP endogenous retroviruses is constrained by cytosine methylation , 1998, Nature Genetics.

[112]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[113]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[114]  S. Clark,et al.  High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.

[115]  Rudolf Jaenisch,et al.  Targeted mutation of the DNA methyltransferase gene results in embryonic lethality , 1992, Cell.

[116]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[117]  M. Fabbri,et al.  Epigenetic regulation of miRNAs in cancer. , 2013, Advances in experimental medicine and biology.

[118]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[119]  L. Aaltonen,et al.  A TARBP 2 mutation in human cancer impairs microRNA processing and DICER 1 function , 2009 .

[120]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.

[121]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Manel Esteller,et al.  How epigenetics integrates nuclear functions. Workshop on epigenetics and chromatin: transcriptional regulation and beyond. , 2005, EMBO reports.

[123]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[124]  International Human Genome Sequencing Consortium.  Initial sequencing and analysis of the human genome , 2001, Nature.

[125]  C. Pratt,et al.  St. Jude Children's Research Hospital. , 1997, Pediatric hematology and oncology.

[126]  Helmut Gernsheim,et al.  W. H. Fox Talbot and the history of photography , 1977 .